SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Biodexa Pharmaceuticals Plc - ADR

Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals is trending amid discussions about its low float, high short interest, and recent news regarding the enrollment of the first patient in a Phase 2a study for its Type 1 diabetes candidate. The community is actively debating the potential for a short squeeze, upcoming data releases, and the impact of news on the stock's price.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is trending due to high trading volume and a volatile price swing, sparking discussions about a potential short squeeze. The community is weighing the impact of a recent lock-up period expiration against bullish signals like high overnight volume and potential institutional accumulation. Some traders are drawing comparisons to similar situations with HOOD and GME, while others debate the long-term prospects of the stock.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending due to a mix of factors including a significant government contract and increased attention to rare earth minerals, with community members discussing the company's growth potential and strategic importance. Discussions also involve the impact of China's export controls on rare earths, potentially benefiting UAMY as a domestic supplier. Bullish sentiment is fueled by the CEO's confidence in the company's future and recent insider buying.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is trending as discussions revolve around its earnings report, which spurred optimism regarding business travel expansion and overall performance. The narrowed FY25 free cash flow view and positive EPS outlook are key talking points. Community members are also weighing in on the potential impact of the FAA delays due to the government shutdown.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending as investors discuss its potential in the AI race, particularly following collaborations with NVDA, GOOG, and OpenAI; the community is excited about a possible breakout and are heavily debating price targets, with many feeling the stock is undervalued compared to peers and ripe for significant gains, while partnerships are seen as a catalyst for growth.

PepsiCo, Inc. engages in the manufacture, marketing, distribution, and sale of beverages, food, and snacks. It operates through the following business segments: Frito-Lay North America (FLNA), Quaker Foods North America (QFNA), PepsiCo Beverages North America (PBNA), Latin America (LatAm), Europe, Africa, Middle East, and South Asia (AMESA), and Asia Pacific, Australia and New Zealand, and China Region (APAC). The FLNA segment consists of branded convenient food businesses in the United States and Canada. The QFNA segment includes cereals, rice, and pasta under the Quaker, Pearl Milling Company, Quaker Chewy, Cap'n Crunch, Life, and Rice-A-Roni brands. The PBNA segment is composed of beverage concentrates, fountain syrups, and finished goods under various beverage brands such as Pepsi, Gatorade, Mountain Dew, Diet Pepsi, Aquafina, Diet Mountain Dew, Sierra Mist, and Mug. The LatAm segment covers beverage, food, and snack businesses in the Latin American region. The Europe segment offers beverage, food, and snack goods in Europe and Sub-Saharan Africa regions. The AMESA segment deals with all beverage and convenient food businesses in Africa, the Middle East, and South Asia. The APAC segment refers to all business operations in the Asia Pacific, Australia and New Zealand, and China region. The company was founded by Donald M. Kendall, Sr. and Herman W. Lay in 1965 and is headquartered in Purchase, NY.

PepsiCo Inc

PepsiCo is trending after exceeding Q2 earnings expectations and maintaining its full-year outlook, leading to community discussions about the company's growth strategy and potential for continued momentum. The appointment of a new CFO is also being discussed. Some analysts believe the stock is undervalued, while others express caution due to volume softness and market conditions.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending due to its partnership with DoorDash for autonomous deliveries, sparking community excitement about the potential impact on the company's growth. Discussions also highlight the stock's high short interest and potential gap fill, with some investors expressing long-term bullish sentiment based on Serve Robotics' innovative approach to last-mile automation. The broader context of robotics and AI in delivery services is also contributing to the increased attention.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

American Airlines is trending as community members discuss its potential breakout and overnight moves, with some highlighting option volumes and call activity. Positive sentiment from Delta's earnings and expectations for upcoming UAL and AAL earnings reports on 10/15 and 10/23, respectively, contribute to the conversation. Some traders express concerns about government shutdowns potentially impacting air travel and future guidance.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending amid speculation of a potential buyout, fueled by recent acquisitions in the obesity and MASH space, with community members citing the company's promising drug pipeline and ongoing Phase 3 trials as key factors.  Discussion is centered on potential suitors and ideal acquisition prices, while also acknowledging the possibility of VKTX pursuing independent development. Some traders point to technical indicators suggesting a potential short squeeze.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors discuss its potential gamma squeeze and high short interest, fueled by growing open call options. Community members are highlighting the company's transition towards AI/HPC data centers and comparing it to other miners in the sector. News of a deal with Google and video coverage are also driving interest and bullish sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CVS vs. EVH: Which Value-Based Care Stock Deserves Investor Attention?

CVS shows revenue growth and raised guidance, while EVH faces revenue declines but pursues oncology deals and efficiency gains.

Evolent Health (EVH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Evolent Health (EVH) Reports Q2 Loss, Misses Revenue Estimates

Evolent Health (EVH) delivered earnings and revenue surprises of -211.11% and -2.86%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

iRhythm Technologies (IRTC) Reports Q2 Loss, Tops Revenue Estimates

iRhythm Technologies (IRTC) delivered earnings and revenue surprises of +39.62% and +7.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Evolent Health (EVH) Q2 Earnings Expected to Decline

Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evolent Health (EVH) Stock Jumps 6.9%: Will It Continue to Soar?

UBS said Friday's update from Evolent Health was “incrementally positive” for the company, citing multiple developments including easing oncology costs, new debt financing, and stable forward guidance.Evolent Health shares rose 6.9% to close at $9.25 on Friday,In a note to investors, UBS highlighted Evolent’s confirmation that oncology cost trends remain below expectations, a key area of concern following a 9% stock decline since April.&nbsp;The company also reiterated Q2 adjusted core profit guidance of $33 million to $40 million, and FY25 guidance of $135 million to $165 million.On Friday, Evolent CFO John Johnson said the company now expects to be in the top half of its Q2 EBITDA range, provided trends continue through June.&nbsp;"We are pleased to see oncology trend remaining below forecast now for the first two-thirds of the quarter," he noted.UBS also pointed to new debt financing from Ares Management, which provides optional, non-dilutive capital to address Evolent’s 2025 convertible notes.&nbsp;The company flagged an expanding late-stage growth pipeline.Despite reporting a solid Q1, UBS noted that EVH shares have lagged, partly driven by market concern over oncology cost pressures.&nbsp;The firm views the latest update as a sign of improving sentiment and stronger financial positioning.On Stocktwits, retail sentiment was ‘neutral’ amid ‘normal’ message volume.One user said Evolent Health’s 52-week high of $33.63 leaves room for a potential upward squeeze.&nbsp;<stembedurl>https://stocktwits.com/BPler/message/618494183</stembedurl>Another user speculated that the stock could reach $15 after the third quarter of 2025.<stembedurl>https://stocktwits.com/TOMKiLA/message/618489336</stembedurl>The stock has declined 19.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Evolent Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

UBS Views Evolent Health’s Q2 Outlook And Financing Moves As ‘Incrementally Positive’

The company reaffirmed its full-year adjusted core profit guidance and noted that oncology cost trends remained below forecast through the first two-thirds of the quarter.

Equity

Evolent Health (EVH) Q1 Earnings Lag Estimates

Evolent Announces Fourth Quarter and Full Year 2024 Results

Evolent Announces Fourth Quarter and Full Year 2024 Results Evolent Announces Fourth Quarter and Full Year 2024 Results PR Newswire WASHINGTON, Feb. 20, 2025 Revenue of $646.5 million for the three...

Evolent Health Announces Changes to Board of Directors

Evolent Health Announces Changes to Board of Directors Evolent Health Announces Changes to Board of Directors PR Newswire WASHINGTON, Feb. 4, 2025 Richard 'Rick'Jelinek to Be Named Chair of the Board...

Evolent Health, Inc. engages in the provision of healthcare delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.

Evolent Health Inc - Ordinary Shares - Class A

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

EVH
Evolent Health Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest EVH News

EVH Evolent Health Inc - Ordinary Shares - Class A